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Abstract
Background Although endoscopic stenting is increas-
ingly performed, surgical gastrojejunostomy (GJ) is still
considered the gold standard for relief of malignant gastric
outlet obstruction (GOO). The aim of this study is to
compare clinical outcomes and hospital costs between
patients undergoing GJ or stenting for management of
malignant GOO.
Methods A retrospective claims analysis of the Medicare
(MedPAR) database was conducted to identify all inpatient
hospitalizations for GJ or endoscopic stenting for malig-
nant GOO during 2007–2008. The main outcome measure
evaluated using the MedPAR database was a comparison of
the total length of hospital stay (LOS) and costs associated
with both techniques. As MedPAR is a claims database that
does not provide outcomes at patient level, a single-insti-
tution retrospective study was conducted to compare the
rates of technical and treatment success, post-procedure
LOS, and delayed complications per patient between the
two techniques.
Results The MedPAR claims data evaluated 425 stenting
and 339 GJ hospitalizations. Compared with GJ, median
LOS (8 vs. 16 days; p \ 0.0001) and median cost (US
$15,366 vs. US $27,391; p \ 0.0001) per claim were both
significantly lower for stenting. Stenting was more com-
monly performed at urban versus rural hospitals (89 % vs.
11 %; p \ 0.0001), teaching versus non-teaching hospitals
(59 % vs. 41 %, p = 0.0005), and academic institutions
(56 % vs. 44 %; p = 0.0157). The institutional patient data
analysis included 29 patients who underwent stenting and
75 who underwent surgical GJ. While both modalities were
technically successful and relieved gastric outlet obstruc-
tion in all cases, compared with surgical GJ, the median
post-procedure LOS was significantly lower for enteral
stenting (1.5 vs. 10.7 days, p \ 0.0001). There was no
difference in rates of delayed complications between
stenting and surgical GJ (13.8 % vs. 6.7 %; p = 0.26).
Conclusions While the technical and clinical outcomes of
surgical GJ and endoscopic stenting appear comparable,
stent placement is less costly and is associated with shorter
length of hospital stay. Dissemination of endoscopic stent-
ing beyond teaching, academic hospitals located in urban
areas as a treatment for malignant GOO is important given
its implications for patient care and resource utilization.
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Gastric outlet obstruction (GOO) is a common symptom,
occurring in 15–20 % of patients with locally advanced
gastrointestinal cancer [1–3]. Clinical manifestations of
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GOO include nausea, vomiting, and dehydration. Tradi-
tionally, surgical gastrojejunostomy (GJ) has been the
standard treatment approach for these patients. Although GJ
relieves symptoms in almost all patients, the procedure is
associated with morbidity of 10–16 % and mortality of up to
7 % [4–6]. Also, post-operatively, most patients suffer
delayed gastric emptying that is often associated with pro-
longed hospital stay [7]. Although laparoscopic GJ has been
introduced as a less invasive alternative to open GJ, the
technique still carries substantial risk and is not widely
available [8–10].
Numerous studies have shown that self-expandable
metal stent (SEMS) placement is a relatively simple and
safe alternative to surgical GJ for management of malignant
GOO [10–12]. The procedure is associated with a technical
success rate of greater than 95 %, and a majority of patients
can tolerate oral intake following stent deployment [11].
Also, compared with surgery, patients undergoing SEMS
placement have shorter length of hospital stay [4, 12]. A
disadvantage of SEMS is the high rate of late complications
caused by stent migration and occlusion [2]. Also, SEMS
are expensive and it is unclear whether their use is less
costly when compared with surgical GJ. Although direct
cost studies have shown that SEMS placement is less costly
than surgery, the general applicability of the data is debat-
able given the small number of patients enrolled in each of
these single-institution trials [13–15].
The objectives of the present study are to (1) compare
the hospital costs and length of stay (LOS) at a national
level by using a claims database and (2) compare the
clinical outcomes at a patient level by conducting a single-
institution retrospective study for patients undergoing sur-
gical GJ versus stenting for management of malignant
GOO.
Patients and methods
This study was conducted in two parts: First, Medicare
Provider Analysis and Review (MedPAR) inpatient hos-
pitalization data were utilized to evaluate hospital costs and
length of stay (LOS) for patients who underwent gastro-
jejunostomy or endoscopic duodenal stenting for relief of
malignant gastric outlet obstruction. Second, since clinical
outcomes may not be evaluated using MedPAR, a retro-
spective study was conducted to evaluate patient outcomes
at an institutional level.
MedPAR data source
A retrospective analysis was conducted utilizing
2007–2008 MedPAR data. This database contains com-
plete inpatient hospitalization claim records for the entire
US Medicare population of 44 million (2007)–45.5 million
(2008) covered lives. MedPAR claims contain information
on patient demographics including age, sex, diagnosis, and
comorbidities. In addition, information regarding hospi-
talization such as LOS, diagnostic testing, therapeutic
procedures, and hospital charges is provided. The MedPAR
dataset was linked to the provider of services (POS) file,
which provides the geographic and demographic informa-
tion for the hospitals where the claims were generated
(location, associations, teaching status, and number of
beds).
Patient population
The study population consisted of all unique hospitaliza-
tion claims for a GJ procedure or endoscopic placement of
a duodenal stent. Claims were included based on primary
diagnosis and procedure. GJ claims were identified by an
obstruction of duodenum diagnosis defined as ICD-9-CM
diagnosis code 537.3 reported with any one of the fol-
lowing cancer diagnoses: pancreas, gallbladder, bile ducts,
biliary tract, small intestine, or duodenum. In addition, the
claim had to have any one of the following surgical GJ
ICD-9-CM procedure codes reported: 44.38 or 44.39.
In 2007–2008, there was no unique ICD-9-CM proce-
dure code to report for endoscopic placement of a duodenal
stent. As such, the following proxy was developed to
identify stent placement claims: the claim had to have an
obstruction of duodenum with cancer diagnosis reported, as
described above. In addition, the stenting claim had to have
the following endoscopy of small intestine ICD-9-CM
procedure code 45.13 reported with revenue code ‘‘0278:
Medical/Surgical Supplies other implant.’’ Claims where
both GJ and stent placement procedures were reported
together were excluded from the analysis.
Outcome measures
Using the MedPAR claims data, the total LOS from
admission to discharge and the total costs associated with
each technique were compared. As per the Medicare cost
report, the hospitalization costs were derived by applying
the appropriate cost-to-charge ratio to the charges reported
in MedPAR. A secondary analysis was also conducted to
analyze demographics of the hospitals in which the pro-
cedures were performed.
Institutional data
As MedPAR is a claims database that does not provide
outcomes at a patient level, a single-institution retrospec-
tive case-control study was conducted where each patient
who underwent stent placement was matched with two
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gastrojejunostomy patients having procedures in the period
2006–2008.
Patient population
A retrospective analysis was conducted of consecutive
patients ([19 years of age) who underwent surgical GJ or
duodenal stenting for management of malignant GOO.
Patients were identified from the endoscopy and surgery
databases. Inclusion criteria were: patient age [19 years,
underlying diagnosis of cancer of the pancreaticobiliary
system, and procedures undertaken for relief of GOO.
Excluded were patients who underwent GJ or stenting for
benign diseases. The medical records of all study subjects
were reviewed for patient demographics, clinical presen-
tation, comorbidities, laboratory investigations, cancer
staging, and radiological investigations.
Duodenal stenting
All SEMS (WALLSTENT or WALLFLEX; Boston Sci-
entific Corp., Natick, MA) were deployed under fluoro-
scopic guidance with the patient in left lateral position
using a combination of intravenous midazolam and
meperidine. The stents measured 22 mm in the body and
27 mm in the proximal flare, and were 6, 9, or 12 cm in
length. At gastroscopy, a 0.035 in guide wire was first
advanced across the stricture. A 5Fr endoscopic retrograde
cholangiopancreatoscopy (ERCP) cannula was then
advanced over the guide wire, and contrast was injected to
assess the length of the stricture. The SEMS delivery sys-
tem was then advanced over the guide wire, and after
satisfactory positioning of the delivery catheter was con-
firmed by fluoroscopy, the SEMS was deployed.
Surgical GJ
Briefly, after making a midline incision, a small opening
was made into both the posterior wall of the stomach and
the jejunal loop with a Harmonic scalpel. The jaws of an
Endo-GIA stapler (3.5 mm/60 mm; US Surgical, Norwalk,
CT) were inserted into the enterotomies, and a wide gas-
trojejunostomy was created by three firings of the stapler.
The staple line was then carefully inspected for bleeding,
and the enterotomies were closed with a running suture.
Outcome measures
The rates of treatment success, complications, re-inter-
ventions, and length of post-procedure hospital stay were
compared between each treatment modality.
Consent
All patients provided informed consent to undergo the
procedures, and the study was approved by the University
of Alabama at Birmingham Institutional Review Board.
Statistical analysis
MedPAR data
All analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC). Discrete data are reported as fre-
quencies, and continuous data are reported as median/
mean. Using a chi-square test, the patient demographics
and comorbidities reported on the claims were compared
across the GJ and stenting cohorts. Covariates were not
adjusted for in the analysis of health resources due to
limitations associated with using MedPAR data.
Institutional data
Statistical analysis was performed by using Stata 9.2
(StataCorp LP, College Station, TX). Patient demographics
and disease characteristics were compared across the two
groups (SEMS stenting and GJ). A two-sample t test was
used to compare the means of the continuous variables
such as age, albumin levels, and Charlson score. A chi-
square test was used to compare the proportions of disease
characteristics (Table 1) and outcome measures (Table 2)
across the two groups.
Results
MedPAR data
A total of 339 GJ and 425 duodenal stent placement claims
met the study inclusion criteria. The age, gender, and
comorbidities of patients in both cohorts are presented in
Table 3. There was no significant difference in gender
distribution between the two groups. With the exception of







Age (mean years) 59.6 62.9 0.2026
Sex (% females) 48.3 58.7 0.3387
Race (% Black) 34.5 27.03 0.4538
Metastasis (% yes) 68.9 80.0 0.3305
Charlson score (mean) 5.97 4.84 0.0305*
* p \ .05
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cerebrovascular disease, diabetes without complications,
and moderate/severe liver disease, there was no significant
difference between the two cohorts for comorbid condi-
tions. Each of these comorbidities was more prevalent in
the stenting group.
Median aggregate hospital days or total LOS from
admission to discharge was 8 versus 16 days for duodenal
stent placement and GJ claims, respectively (p \ 0.0001).
Stent placement claims had significantly lower total med-
ian hospital costs per claim than GJ claims (US $15,366 vs.
US $27,391; p \ 0.0001) (Fig. 1). Mean hospital costs for
the stent placement cohort were US $20,133 versus US
$35,444 for the GJ cohort (p \ 0.0001).
Stent placement was more commonly performed in
urban versus rural hospitals (89 % vs. 11 %; p \ 0.0001),
teaching versus non-teaching hospitals (59 % vs. 41 %;
p = 0.0005), and academic institutions (56 % vs. 44 %;
p = 0.0157).
Institutional data
The single-institution retrospective study involved 29
patients who underwent SEMS placement and 75 patients
who underwent surgical GJ for malignant GOO. Table 1
displays demographics and disease characteristics of all
patients at presentation. There was no significant difference
between cohorts with regard to patient demographics or
presence of metastasis. Patients who underwent stent
placement had significantly higher comorbidities as indi-
cated by their Charlson scores.
Surgical GJ and SEMS placements were successful in
relieving the obstruction in all patients. While the mean
duration of post-procedure LOS was significantly shorter
(1.52 vs. 10.72 days, p \ 0.0001), there was no difference
in pre-procedure LOS (2 vs. 3.4 days, p = 0.52) between
patients who underwent SEMS placements versus surgery,
respectively. Although there were no complications in the
immediate postintervention period among patients who
underwent SEMS placement, six patients in the surgical







Relief of obstruction (%) 100 100 1
Intra-procedural
complications (n, %)
0 (0) 0 (0) 1




* p \ .05
Table 3 Baseline demographics and comorbid conditions of the stent
placement and gastrojejunostomy patient populations as reported in










45–64 8 6 0.176
65–69 16 22 0.019
70–74 17 20 0.301
75–79 20 19 0.983
80–84 18 20 0.564
85–89 13 9 0.099
[89 7 3 0.011
























Renal disease 4 4 0.818
Fig. 1 Median inpatient hospital costs per claim for duodenal
stenting claims versus gastrojejunostomy claims (MedPAR data)
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cohort encountered complications (0 % vs. 8 %, p = 0.18)
that included death from sepsis (n = 1, post-operative day
9), wound infection (n = 2), and delayed gastric emptying
that required placement of a temporary nasoenteric feeding
tube via the surgical anastomosis (n = 3). Delayed com-
plications were encountered in four patients in the SEMS
cohort [median (range): 97 (83–139) days] compared with
five patients in the surgical cohort [median (range): 41
(26–61) days] (13.8 vs. 6.7 %; p = 0.26). Complications in
the SEMS cohort included stent occlusion in three patients
and small bowel perforation from a migrated stent in one.
Two of three patients with stent occlusion were managed
by placement of additional stents, and one patient was
treated with balloon dilation; the small bowel perforation
was managed by surgical removal of the stent with repair
of the perforation and a surgical GJ. Three of four patients
admitted for delayed complications were discharged within
24 hours of reintervention, and the patient who underwent
surgery required a 7 day hospitalization. The mean dura-
tion of hospitalization for delayed complications was
2.5 days (range 1–7 days) for the stenting cohort. Delayed
complications in the surgical cohort included bowel
obstruction that required exploratory laparotomy with lysis
of adhesions in three patients and delayed gastric emptying
due to an anastomotic stricture that required gastroscopy
with dilation in two patients. The mean duration of hos-
pitalization for delayed complications was 5.2 days (range
2–9 days) for the surgical cohort.
Of the 29 patients who underwent SEMS placement, at
median follow-up of 5 months (range 1–11 months), 25
patients had died and 4 were lost to follow-up. Of the 75
patients who underwent surgical GJ, at median follow-up
of 6 months (range 1–13 months), 67 had died, 3 were
receiving palliative chemotherapy, and 5 were lost to fol-
low-up. There was no difference in median duration of
survival between the SEMS and surgical GJ cohorts (118
vs. 132 days, respectively; p = 0.67).
Discussion
The main objective of a palliative procedure in patients
with malignant GOO is to restore their ability to eat.
Several studies have shown that SEMS placement is a safe
and effective alternative to surgery [10–12]. A compre-
hensive review of 32 case series including 606 patients
unable to take oral intake reported successful stent
deployment in 97 % of patients, and oral intake was pos-
sible in all successful cases, with 87 % of patients capable
of eating at least a mechanical soft diet [11]. There are
limited reports comparing stenting of the gastric outlet or
small intestine with surgical bypass. A small randomized
prospective study of 18 patients comparing SEMS
placement versus surgical bypass found no difference in
survival, complication rates, or gastric emptying at
3 months, but the SEMS group had more rapid restoration
of oral intake and shorter mean hospitalization [12]. Sim-
ilarly, a retrospective comparison of a cohort of 27 patients
with pancreatic cancer causing duodenal obstruction trea-
ted with endoscopic stenting versus surgical bypass found
no difference in survival but median hospital stay of 4 days
in the stent group versus 14 days in the surgical group [4].
A prospective nonrandomized study of 36 patients found
no difference in overall survival or ability to tolerate food
1 month after stent placement or surgical bypass [13]. In
the present study that evaluated claims data of 764 patients,
the median LOS per claim was 8 versus 16 days for the
SEMS and surgical GJ cohorts, respectively. While total
length of hospital stay can be estimated using the MedPAR
database, it is not possible to assess the post-procedure
LOS. When these clinical outcomes were evaluated at
institutional level, the difference in post-procedure LOS
was even more pronounced: 1.5 versus 10.7 days. Even in
the absence of complications, surgical patients required
lengthier post-procedure hospitalization for pain manage-
ment and tolerance of oral intake. Similar to prior reports
[4, 10–12], our analysis of institutional data found no
significant difference in rates of treatment success, proce-
dural or delayed complications, or median duration of
survival between the two groups.
While three prior single-institution studies, two from
Europe and one from the USA, have shown that stent
placement was significantly less costly than surgery, this
has never been examined from a national perspective. In
the present study, the median cost per claim was US
$12,025 lower for patients undergoing SEMS placement.
These findings, involving 425 SEMS and 339 surgical
claims, are more realistic representations of the costs
associated with both treatment modalities in the US
population.
Analysis of the claims data revealed that, despite its
inherent clinical advantages and cost savings, duodenal
stenting is more commonly performed at large, urban,
teaching hospitals. We speculate that, in large teaching
institutions, better collaboration between the disciplines of
medical gastroenterology and general surgery results in
more patients undergoing SEMS placement. In smaller and
rural hospitals, patients are probably managed based on the
manner in which they are triaged at admission: those
admitted to the gastroenterology service are more likely to
undergo stent placement, whereas those admitted to the
surgical service undergo resection. It is our opinion that, at
least for patients with multiple comorbidities and poor
functional status, duodenal stent placement should be the
favored initial treatment approach, as these patients are
poor operative candidates. More education and training is
3118 Surg Endosc (2012) 26:3114–3119
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needed to propagate appropriate use of stenting in patients
presenting with malignant GOO.
Our study suffers from some limitations. As it would
have been ideal to have conducted a longitudinal study
evaluating the two cohorts from the initial procedure to
death, tracking procedures performed and associated costs,
the inability to conduct a longitudinal analysis is one of the
limitations of analyses of the MedPAR claims database.
There are no unique patient identifiers to track the same
patient over time. The MedPAR database only allows for
cross-sectional studies to be performed. In addition, out-
comes data, such as procedural success and complication
rates, cannot be evaluated using a claims database. It is also
possible that some of these patients who underwent sur-
gical GJ had failed attempts at prior stent placement. At an
institutional level, as patients were not followed prospec-
tively, it is likely that some minor adverse events were not
captured. Also, it is possible that outcomes were influenced
by patient characteristics in each group. However, this may
not be a major limitation as patients undergoing SEMS had
higher Charlson scores (5.97 vs. 4.84, p = 0.03). In addi-
tion, this retrospective study examined a small sample of
patients from a single institution. As a result, the ability to
generalize these findings to a national sample is limited and
is not the intent of this study. Being a retrospective study,
we could not present data on the rates of technical failure in
the SEMS cohort or on the number of patients who failed
stent placement and subsequently underwent surgery.
In conclusion, while the technical and clinical outcomes
of GJ and stent placement appear comparable in relieving
obstruction, stent placement is less costly and is associated
with shorter LOS. Dissemination of stent placement
beyond teaching hospitals located in urban areas as a
treatment for malignant GOO is important given its
implications for patient care and resource use.
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